This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s […]
Biotechnology in Countries Beginning with “I” – Part 9: Iran Read Post »
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Once in a Blue Moon: When BIO and DIA Worlds Collide #BIO2015 #DIA2015 Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Dyslipidaemia: Focus shifts from LDL-C to HDL-C
Go to paperABSTRACT: In this current analysis of the antidyslipidaemics market, a shift in focus from lo…
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents
Venture capitalists (VCs) aim at trade sales as a preferred exit-strategy for biotechnology companies they invest in. Therefore, VCs pay close attention to the wishes of larger (bio)pharmaceutical acquirers. In this paper we explore VCs’ behavior and strategies by analyzing the technology fields and therapeutic areas in which they are invested most and which yield the highest returns by means of trade sales. The data show that VCs are by far most invested in oncology and this is also an area in which relatively high returns are realized. Regarding other areas, VCs could balance their average investment valuations more in correspondence with what acquirers are willing to pay. In addition, VCs have formidable insight in the types of technologies that do well and they seem to employ a strategy focused on both short-term and long-term success. They are investing most in small molecule drugs and protein/peptide therapeutics, which both yield high returns, followed by DNA/RNA technologies which underlie the possibilities of personalized medicine. We conclude that Venture Capitalists act as technological gatekeepers because they are predicting long-term cure and care macro-trends.
Venture Capitalists as gatekeepers for Biotechnological Innovation Read Post »
Biopharmaceutical companies have the most complete and up-to-date information about the medicines that they research, develop and manufacture for use by patients. However, companies are often unable to proactively share valuable information about their medicines, especially for information that is not contained in the FDA-approved prescribing information (the package insert you often receive with a prescription), with physicians and other healthcare providers.
The new FDA draft guidance opens the door for companies to share truthful, scientifically accurate, and data-driven information with healthcare professionals to inform treatment decisions.